Skip to content

Acebutolol Hydrochloride

FDA-approved product (capsule, oral), marketed as Acebutolol Hydrochloride, Sectral.

Registered studies
12
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Acebutolol Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Hypertension
  • Ventricular arrhythmia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Beta blocking agents, selective
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA21.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli26.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

12registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Acebutolol Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Preliminary Study for INFORMED

    NCT05585125 · start 2024-02-07

    Registered record
    Registry ID
    NCT05585125
    Conditions
    Heart Failure; Heart Failure, Diastolic; Heart Failure With Preserved Ejection Fraction; Cardiac Failure; Heart Diseases
    Interventions
    Beta blocker; Beta blocker
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-02-07
    Completion
    2027-11
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure; Heart Failure, Diastolic; Heart Failure With Preserved Ejection Fraction; Cardiac Failure +1 more
    InterventionBeta blocker; Beta blocker
    PhasePhase 4
    Registry statusRecruiting
  • N-of-1 for Beta-Blockers in Cardiac Amyloidosis

    NCT05019027 · start 2024-01-31

    Registered record
    Registry ID
    NCT05019027
    Conditions
    Cardiac Amyloidosis; Heart Diseases; TTR Cardiac Amyloidosis
    Interventions
    Beta blocker
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2024-01-31
    Completion
    2026-06-04
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiac Amyloidosis; Heart Diseases; TTR Cardiac Amyloidosis
    InterventionBeta blocker
    PhasePhase 4
    Registry statusCompleted
  • Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF

    NCT04757584 · start 2021-04-01

    Registered record
    Registry ID
    NCT04757584
    Conditions
    Heart Failure; Heart Failure, Diastolic; Heart Failure With Preserved Ejection Fraction; Cardiac Failure; Heart Disease
    Interventions
    Beta blockers
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-04-01
    Completion
    2023-04-28
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure; Heart Failure, Diastolic; Heart Failure With Preserved Ejection Fraction; Cardiac Failure +1 more
    InterventionBeta blockers
    PhasePhase 4
    Registry statusCompleted
  • Impact of Beta-blockers on Physical Function in HFpEF

    NCT04767061 · start 2021-04-01

    Registered record
    Registry ID
    NCT04767061
    Conditions
    Heart Failure; Heart Failure, Diastolic; Heart Failure With Preserved Ejection Fraction; Cardiac Failure; Heart Disease
    Interventions
    Beta blockers
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-04-01
    Completion
    2023-04-28
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure; Heart Failure, Diastolic; Heart Failure With Preserved Ejection Fraction; Cardiac Failure +1 more
    InterventionBeta blockers
    PhasePhase 4
    Registry statusCompleted
  • ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

    NCT04467931 · start 2020-01-19

    Registered record
    Registry ID
    NCT04467931
    Conditions
    Hypertension; COVID
    Interventions
    ACEI/ARB; Non-ACEI/ARB; ACEI; ARB
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-01-19
    Completion
    2020-12-31
    Enrolment
    22,213

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; COVID
    InterventionACEI/ARB; Non-ACEI/ARB; ACEI; ARB
    PhaseNot recorded
    Registry statusCompleted
  • Efficacy and Safety of Propranolol Versus Acebutolol on the Proliferative Phase of Infantile Hemangioma

    NCT01743885 · start 2012-11

    Registered record
    Registry ID
    NCT01743885
    Conditions
    Hemangioma
    Interventions
    Acebutolol; Propanolol
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2012-11
    Completion
    2015-06
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHemangioma
    InterventionAcebutolol; Propanolol
    PhasePhase 3
    Registry statusTerminated
  • An Open-label, Single-dose, Two-treatment, Randomized, Cross-over Study to Investigate the Effects of the SLCO2B1 c.1457C>T Polymorphism and Apple Juice on the Pharmacokinetics and Pharmacodynamics of Acebutolol in Healthy Korean and Japanese Volunteers

    NCT01514019 · start 2012-01

    Registered record
    Registry ID
    NCT01514019
    Conditions
    Healthy
    Interventions
    Acebutolol; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-01
    Completion
    2012-05
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionAcebutolol; Placebo
    PhasePhase 4
    Registry statusCompleted
  • Coreg and HSRs-Updated Analysis

    NCT01316952 · start 2010-06

    Registered record
    Registry ID
    NCT01316952
    Conditions
    Hypersensitivity
    Interventions
    Carvedilol immediate release only; Carvedilol extended release only; Long acting β-blockers; Other α1/β-adrenergic antagonists; Short acting Non-selective β-blockers and short acting β1-Selective agents; No β-blocker
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-06
    Completion
    2011-03
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypersensitivity
    InterventionCarvedilol immediate release only; Carvedilol extended release only; Long acting β-blockers; Other α1/β-adrenergic antagonists +2 more
    PhaseNot recorded
    Registry statusCompleted
  • Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

    NCT00911508 · start 2009-11-13

    Registered record
    Registry ID
    NCT00911508
    Conditions
    Atrial Fibrillation; Arrhythmia
    Interventions
    Left atrial ablation; Rate or Rhythm Control Therapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-11-13
    Completion
    2017-12-31
    Enrolment
    2,204

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Arrhythmia
    InterventionLeft atrial ablation; Rate or Rhythm Control Therapy
    PhaseNot applicable
    Registry statusCompleted
  • Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial

    NCT00578617 · start 2006-09

    Registered record
    Registry ID
    NCT00578617
    Conditions
    Atrial Fibrillation; Arrhythmia
    Interventions
    Rate Control; Ablation Therapy; Rate Control; Rate control; Rate control; Rate control; Rate Control; Rate Control; Rate Control; Rhythm Control; Rhythm control; Rhythm control; Rhythm control; Rhythm control; Rhythm control
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-09
    Completion
    2010-06
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Arrhythmia
    InterventionRate Control; Ablation Therapy; Rate Control; Rate control +11 more
    PhaseNot applicable
    Registry statusCompleted
  • Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension

    NCT00684489 · start 2003-09

    Registered record
    Registry ID
    NCT00684489
    Conditions
    Hypertension
    Interventions
    clinical hypertension specialist-no specific med. Any anti-hypertension meds.; renin guided therapeutics-no specific med. Any anti-hypertensive med.
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-09
    Completion
    2005-09
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionclinical hypertension specialist-no specific med. Any anti-hypertension meds.; renin guided therapeutics-no specific med. Any anti-hypertensive med.
    PhaseNot applicable
    Registry statusCompleted
  • Treatment of Mild Hypertension Study (TOMHS)

    NCT00000522 · start 1985-08

    Registered record
    Registry ID
    NCT00000522
    Conditions
    Cardiovascular Diseases; Heart Diseases; Hypertension; Vascular Diseases
    Interventions
    diet, sodium-restricted; diet, reducing; exercise; alcohol restriction; chlorthalidone; acebutolol; doxazosin; amlodipine; enalapril
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1985-08
    Completion
    1994-05
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases; Heart Diseases; Hypertension; Vascular Diseases
    Interventiondiet, sodium-restricted; diet, reducing; exercise; alcohol restriction +5 more
    PhasePhase 2
    Registry statusCompleted